CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

But while an improved reputation can be a by-product of patient engagement, it should not be the driving force behind it.

To better detect cardiovascular diseases in people, researchers used high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) to simultaneously quantify metabolites in human plasma ...

Certara, Inc., a global leader in biosimulation, announced that the European Medicines Agency (EMA) has formally qualified the Simcyp Simulator for use in regulatory submissions across the EU. Certara ...

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...

The IND clearance allows Hemispherian to proceed with a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GLIX1 in patients with ...

DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

Weight loss drugs could soon be used to treat these seven other health conditions - Eli Lilly and Novo Nordisk are actively ...

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

The FDA has granted breakthrough therapy designation to DYNE-251 for the treatment of DMD in patients amenable to exon 51 ...

The most special thing about a vaccine is that it not only controls or reduces the disease, but taking it does not cause the ...